Table of Content

1. Report Introduction

2. Intrahepatic Cholangiocarcinoma
2.1. Intrahepatic Cholangiocarcinoma Disease Overview
2.2. Intrahepatic Cholangiocarcinoma History
2.3. Intrahepatic Cholangiocarcinoma Symptoms
2.4. Intrahepatic Cholangiocarcinoma Causes
2.5. Intrahepatic Cholangiocarcinoma Pathophysiology
2.6. Intrahepatic Cholangiocarcinoma Diagnosis
2.6.1. Diagnostic Guidelines

3. Intrahepatic Cholangiocarcinoma Current Treatment Patterns
3.1. Treatment Guidelines

4. Intrahepatic Cholangiocarcinoma - DelveInsight’s Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Intrahepatic Cholangiocarcinoma companies collaborations, Licensing, Acquisition –Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Intrahepatic Cholangiocarcinoma Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Intrahepatic Cholangiocarcinoma Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono / Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA

5. Intrahepatic Cholangiocarcinoma Pipeline Therapeutics
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products

6. Intrahepatic Cholangiocarcinoma - Products Analysis
6.1. Product Profiles
6.1.1. Melphalan: Delcath Systems
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
6.1.2. STP705: Sirnaomics
6.1.2.1. Product Description
6.1.2.1.1. Product Overview
6.1.2.1.2. Mechanism of Action
6.1.2.2. Research and Development
6.1.2.2.1. Clinical Studies
6.1.2.2.1.1. Detailed Study Description
6.1.2.2.1.2. Study Results
6.1.2.2.1.3. Clinical Trials: Tabular View
6.1.2.3. Product Development Activities
6.1.2.3.1. Tabulated Product Summary
6.1.2.3.1.1. General Description Table
6.1.3. Opaganib: RedHill Biopharma
6.1.3.1. Product Description
6.1.3.1.1. Product Overview
6.1.3.1.2. Mechanism of Action
6.1.3.2. Research and Development
6.1.3.2.1. Clinical Studies
6.1.3.2.1.1. Detailed Study Description
6.1.3.2.1.2. Study Results
6.1.3.2.1.3. Clinical Trials: Tabular View
6.1.3.3. Product Development Activities
6.1.3.3.1. Tabulated Product Summary
6.1.3.3.1.1. General Description Table
To be continued in the report??????????

7. Recent Technologies

8. Intrahepatic Cholangiocarcinoma Key Companies
8.1. ArQule
8.2. H3 Biomedicine
8.3. Delcath System
8.4. Sirnaomics
8.5. RedHill Biopharma
8.6. Roche
8.7. Forma Therapeutics
8.8. Jiangsu Hengrui Medicine
8.9. Biocompatibles International
8.10. LSK BioPartners
8.11. Eisai Co Ltd
8.12. Array BioPharma
8.13. Bayer Healthcare
8.14. Taiho Oncology
8.15. Sirtex Medical
8.16. MedImmune
8.17. Rafael Pharmaceuticals

9. Intrahepatic Cholangiocarcinoma Key Products
9.1. Derazantinib
9.2. H3B 6527
9.3. Melphalan (Primary)
9.4. STP 705
9.5. Opaganib
9.6. Capecitabine (Primary) ; Yttrium-90 (Primary)
9.7. FT 2102
9.8. Camrelizumab
9.9. Irinotecan-eluting beads
9.10. Rivoceranib
9.11. Lenvatinib
9.12. Varlitinib
9.13. Regorafenib
9.14. Futibatinib
9.15. Cisplatin-gemcitabine
9.16. Durvalumab
9.17. CPI 613

10. Dormant and Discontinued Products
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation

11. Intrahepatic Cholangiocarcinoma - Unmet Needs

12. Intrahepatic Cholangiocarcinoma - Future Perspectives

13. Appendix

14. Report Methodology
14.1. Secondary Research
14.2. Expert Panel Validation



List of Tables


Table 1. Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Intrahepatic Cholangiocarcinoma Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products